“This appears to be a very safe and effective drug, and is a valuable part of our therapeutic armamentarium. I don’t think teriflunomide addresses all the unmet needs in MS, in fact, no drug meets all the unmet needs, but this is a very well tolerated oral agent.”
The nearly 7-year extension trial presented a 47% reduction overall in conversion to clinically definite MS with those patients who had been on 14mg of teriflunomide from the beginning.
Ocrevus reduced all 3 aspects of relapsing MS disease: reduction relapses, reduction disability, and reduction lesions within the brain quite substantially.
Patients with tardive dyskinesia were previously only looked at, not treated.